RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bernard Arulanandam to Immunity, Mucosal

This is a "connection" page, showing publications Bernard Arulanandam has written about Immunity, Mucosal.
Connection Strength

0.492
  1. Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999 Oct; 180(4):940-9.
    View in: PubMed
    Score: 0.171
  2. Ainsworth S, Ketter PM, Yu JJ, Grimm RC, May HC, Cap AP, Chambers JP, Guentzel MN, Arulanandam BP. Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection. Vaccine. 2017 06 08; 35(26):3387-3394.
    View in: PubMed
    Score: 0.145
  3. Signarovitz AL, Ray HJ, Yu JJ, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Mucosal immunization with live attenuated Francisella novicida U112?iglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One. 2012; 7(10):e47639.
    View in: PubMed
    Score: 0.106
  4. Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2007 Feb; 75(2):666-76.
    View in: PubMed
    Score: 0.070
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support